Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib

International Journal of Cancer

Volumn 117, Issue 2, 2005, Pages 316-325

  Bauer, Sebastian ^a,f   Hartmann, Jörg Thomas ^d   De Wit, Maike ^c   Lang, Hauke ^a   Grabellus, Florian ^a   Antoch, Gerald ^a   Niebel, Wolfgang ^a   Erhard, Jochen ^b   Ebeling, Peter ^a   Zeth, Matthias ^a   Taeger, Georg ^a   Seeber, Siegfried ^a   Flasshove, Michael ^a   Schütte, Jochen ^e  

^a UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

^b EVANGELISCHES KRANKENHAUS   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e MARIEN HOSPITAL DÜSSELDORF   (Germany)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

GIST; Imatinib; Resection

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IMATINIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRAOPERATIVE PERIOD; MAJOR CLINICAL STUDY; MALE; METASTASIS; MINIMAL RESIDUAL DISEASE; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; TREATMENT OUTCOME; ULTRASOUND; WOUND HEALING IMPAIRMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM, RESIDUAL; PIPERAZINES; PYRIMIDINES; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 25444513214     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.21164     Document Type: Article

References (29)

1. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad TG, Matsuzawa Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-80.
2. Singer S, Rubin BP, Lux ML, Chen CJ, Demetri GD, Fletcher CD, Fletcher JA. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002;20:3898-905.
3. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-10.
4. Graadt van Roggen JF, van Velthuysen ML. Hogendoorn PC. The histopathological differential diagnosis of gastrointestinal stromal tumours. J Clin Pathol 2001;54:96-102.
5. Miettinen M, Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001;438:1-12.
6. Dematteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-8.
7. Dematteo RP, Heinrich MC, El Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002;33:466-77.
8. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-45.
9. Demetri GD, Von Mehren M. Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
10. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PC, Van Glabbeke M, Bertulli R, Judson I. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364: 1127-34.
11. Blanke CD, Joensuu H, Demetri G, Heinrich M, Roberts B, Eisenberg B, Fletcher J, Fletcher CD, Corless C, Dimitrijevic S, Van den Abbeele A, Kiese B, et al. Long-term follow up of advanced gastrointestinal stromal tumor (GIST) patients treated with imatinib mesylate. GI Cancer Symposium 2004. ASCO. Jan 22-24, 2004. San Fransisco, CA.
12. Antman K, Crowley J, Balcerzak SP, Rivkin SE, Weiss GR, Elias A, Natale RB, Cooper RM, Barlogie B, Trump DL. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993;11:1276-85.
13. Rankin C, Von Mehren B, Blanke C, Benjamin RS, Fetcher CDM, Bramwell V, Crowley J, Borden E, Demetri GD. Dose effect of imatinib (IM) in patients (pts) with metastatic GIST - Phase III Sarcoma Group Study S0033. Proc Am Soc Clin Oncol 2004;22(Suppl):9005.
14. Bauer S, Corless CL, Heinrich MC, Dirsch O, Antoch G, Kanja J, Seeber S, Schutte J. Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT. Cancer Chemother Pharmacol 2003;51:261-5.
15. Ng EH, Pollock RE, Munsell MF, Atkinson EN, Romsdahl MM. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992;215:68-77.
16. Ng EH, Pollock RE, Romsdahl MM. Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas. Cancer 1992;69: 1334-41.
17. Dematteo RP, Shah A, Fong Y, Jarnagin WR, Blumgart LH, Brennan MF. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg 2001;234:540-7.
18. Lang H, Nussbaum KT, Kaudel P, Fruhauf N, Flemming P, Raab R. Hepatic metastases from leiomyosarcoma: a single-center experience with 34 liver resections during a 15-year period. Ann Surg 2000;231: 500-5.
19. Billingsley KG, Burt ME, Jara E, Ginsberg RJ, Woodruff JM, Leung DH, Brennan MF. Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and post metastasis survival. Ann Surg 1999;229:602-10.
20. Scaife CL, Hunt KK, Patel SR, Benjamin RS, Burgess MA, Chen LL, Trent J, Raymond AK, Cormier JN, Pisters PW, Pollock RE, Feig BW. Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate? Am J Surg 2003;186:665-9.
21. Lang H, Radtke A, Hindennach M, Schroeder T, Fruehauf NR, Peitgen HO, Malago M, Bourquain H, Oldhafer KJ, Broelsch CE. Impact of virtual tumor resection and computer-assisted risk analysis on operation planning and intraoperative strategy in major hepatic resection. Arch Surg 2005 (in press).
22. Hohenberger P, Schneider U, Pink D, Emmerich K, Kettelhack C, Roetschke O, Reichhardt P. Resection of progressive or residual tumor after treatment with imatinib for advanced GI stromal tumors. Ann Surg Oncol 2004;11(Suppl):s53.
23. Demetri GD. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. Semin Oncol 2001;28(Suppl): 19-26.
24. Bumming P, Andersson J, Meis-Kindblom JM, Klingenstierna H, Engstrom K, Stierner U, Wangberg B, Jansson S, Ahlman H, Kindblom LG, Nilsson B. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. Br J Cancer 2003;89:460-4.
25. Verweij J, Casali PG, Zalcberg J, Le Cesne A, Reichard P, Blay JY, Issels RD, Van Glabbeke M, Donate Di Paola E, Judson IR. Early efficacy comparison of two doses of imatinib for the treatment of advanced gastro-intestinal stromal tumors (GIST): interim results of a randomized phase III trial from the EORTC-STBSG, ISG and AGITG. Proc Am Soc Clin Oncol 2003;22:a3272(abstract).
26. Maki RG. Gastrointestinal stromal tumors respond to tyrosine kinase-targeted therapy. Curr Treat Options Gastroenterol 2004;7:13-7.
27. Duensing A, Medeiros F, McConarty B, Joseph NE, Panigrahy D, Singer S, Fletcher CD, Demetri GD, Fletcher JA. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene 2004;23:3999-4006.
28. Antoch G, Kanja J, Bauer S, Kuehl H, Renzing-Koehler K, Schuette J, Bockisch A, Debatin JF, Freudenberg LS. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 2004;45:357-65.
29. Blay JY, Berthaud P, Perol D, Ray-Coquard I, Bui B, Duffaud F, Braud AC, Rios M, Ducimetiere F, Le Cesne A. Continuous vs intermittent imatinib treatment in advanced GIST after one year: a prospective randomized phase III trial of the French Sarcoma Group. Proc Am Soc Clin Oncol 2004;22(Suppl):9006.